Schering-Plough's peginterferon (PEG IFN)- -2b plus ribavirin [Peg-Intron plus Rebetol] has been granted priority review status in Japan for a new indication

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1495, 2005-01, pp. : 23-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tiotropium bromide [Spiriva; Boehringer Ingelheim] and peginterferon- -2b plus ribavirin [Peg-Intron plus Rebetol; Schering-Plough] have been recommended for approval

By  

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Peginterferon-α-2b [Pegintron; Schering-Plough] has been approved by the Chinese State Food and Drug Administration for chronic hepatitis B;

By  

Inpharma, Vol. 1, Iss. 1584, 2007-01 ,pp. : 27-27

Adis International

Access to resources Recommend Favorite

PEG IFN- -2b plus ribavirin worth its cost in chronic hepatitis C

By  

Inpharma, Vol. 1, Iss. 1379, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

A 23% market share of new prescriptions for hepatitis C in the US has been captured by Roche's antiviral agent PEG-interferon (IFN)- -2a

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 402, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Evaluating EVR to PEG IFN-α-2b/ribavirin therapy worthwhile

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 491, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite